Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-22

Study Completion Date

2022-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc. is the marketing authorization holder for prazosin HCl oral capsules and intended to transfer drug product manufacturing operations from Pfizer, Barceloneta Puerto Rico to Pfizer Pharmaceutical, Ascoli, Italy. To support the manufacturer site transfer and process changes, this bioequivalence (BE) study is being conducted.

This study will be a 2 Cohort, open-label, randomized, single dose study in healthy adult male and/or female participants. Cohort 1 will be crossover with 3 treatments, 3 periods, 6 sequences. Cohort 2 will be crossover with 2 treatments, 2 periods, 2 sequences. Primary objective of this study is demonstrate bioequivalence between prazosin HCl 1, 2 and 5 mg capsules manufactured at Ascoli versus prazosin HCl 2 and 5 mg capsules manufactured at Barceloneta under fasting conditions in healthy adult participants. Approximately 36 participants will be enrolled in each Cohort 1 and Cohort 2.

Pharmacokinetic and statistical analysis will be performed for prazosin. Data from 2 Cohorts will be analyzed separately. The PK parameters area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast), and from time zero extrapolated to infinite time (AUCinf), maximum plasma concentration (Cmax), time to first occurrence of Cmax (Tmax), and terminal phase elimination half-life (t½) will be summarized descriptively by analyte and treatment.

For primary objective, bioequivalence of the Test treatment relative to Reference treatment will be concluded if the 90% confidence intervals (CI) for the ratio of adjusted geometric means of Test treatments relative to Reference treatment for AUCinf (if data permit), AUClast and Cmax, fall wholly within (80%, 125%).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

NCT07231978

Healthy

ACTIVE_NOT_RECRUITING PHASE1

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT04691154

Pulmonary Arterial Hypertension Pulmonary Hypertension Due to Lung Diseases

ACTIVE_NOT_RECRUITING PHASE3

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

NCT03884465

Pulmonary Arterial Hypertension

TERMINATED PHASE2

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

NCT01473108

Clinical Pharmacology

COMPLETED PHASE1

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604

Primary Pulmonary Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site

One 2 mg capsule manufactured at the current site, Barceloneta

Group Type ACTIVE_COMPARATOR

Prazosin HCl 2mg

Intervention Type DRUG

Prazosin HCL 1 X 2 mg capsule.

Prazosin HCL 2 mg capsule Ascoli site

One 2 mg capsule manufactured at the proposed site (Ascoli)

Group Type EXPERIMENTAL

Prazosin HCl 2mg

Intervention Type DRUG

Prazosin HCL 1 X 2 mg capsule.

Prazosin HCL 1 mg capsule Ascoli site

Two 1 mg capsule manufactured at the proposed site, Ascoli

Group Type EXPERIMENTAL

Prazosin HCl 1 mg

Intervention Type DRUG

Prazosin HCl 2 X 1 mg capsule.

Prazosin HCL 5 mg capsule Barceloneta site

One 5 mg capsule manufactured at the current site, Barceloneta

Group Type ACTIVE_COMPARATOR

Prazosin HCl 5 mg

Intervention Type DRUG

Prazosin HCL 1 X 5 mg capsule.

Prazosin HCL 1 x 5 mg capsule Ascoli site

One 5 mg capsule manufactured at the proposed site, Ascoli

Group Type ACTIVE_COMPARATOR

Prazosin HCl 5 mg

Intervention Type DRUG

Prazosin HCL 1 X 5 mg capsule.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prazosin HCl 2mg

Prazosin HCL 1 X 2 mg capsule.

Intervention Type DRUG

Prazosin HCl 1 mg

Prazosin HCl 2 X 1 mg capsule.

Intervention Type DRUG

Prazosin HCl 5 mg

Prazosin HCL 1 X 5 mg capsule.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Minipress 2 mg capsule. Minipress 1 mg capsule. Minipress 5 mg capsule.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be 18 to 55 years of age, inclusive, at the time of signing the Informed Consent Document (ICD).
* Male and female participants who are overtly healthy as determined by medical evaluation including medical history, full physical examination, vital signs, 12-lead electrocardiogram (ECG), and/or clinical laboratory tests.
* Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations , and other study procedures.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).
* Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* History of Human Immunodeficiency Virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb) or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
* Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
* A positive urine drug test.
* Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
* Baseline standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
* Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥1.5 × upper limit of normal (ULN);
* Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
* History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
* Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. For chewing tobacco, one chew is equivalent to approximately 2 to 3 cigarettes, so participants would be limited to 2 or less chews per day.
* History of sensitivity to prazosin hydrochloride or any of the components in the formulation of the study products.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes